secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibrx Biosciences, Inc. (INBX)
CIK:        0002007919
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0002007919-24-000060
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inhibrx Biosciences Q3 net loss $43.9M ($2.84/shr); cash $196.3M; trial readouts in next 12 months
--------------------------------------------------------------------------------

- Cash and cash equivalents $196.3M as of Sep 30, 2024, down from $226.9M at June 30, 2024.
- Net loss of $43.9M ($2.84 per share) vs $51.8M ($4.39 per share) in Q3 2023.
- R&D expense $38.9M, up slightly from $38.1M, driven by expansion of Phase 2 trial for ozekibart (INBRX-109) and INBRX-106 trials.
- No outstanding third-party debt post-spin-off; other income of $2.9M from interest on cash balances.
- Company expects data readouts for its two ongoing clinical programs within the next 12 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2007919/000200791924000060/0002007919-24-000060-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2007919/000200791924000060/inhibrx-20241114.htm
  HTML page:      https://secwatch.observer/filing/0002007919-24-000060

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer